Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human, Primate

Cited:

Human, Mouse, Rat

Applications

Validated:

Immunohistochemistry, Western Blot, ELISA Capture (Matched Antibody Pair), Neutralization

Cited:

Immunohistochemistry, Immunohistochemistry-Frozen, Western Blot, Neutralization, Flow Cytometry, Immunocytochemistry, Affinity Chromatography, Antibody Array Development, Array Development, Bioassay, Biosensor Analysis, Capture Assay, Electrochemiluminescent Assay, ELISA Capture, ELISA Detection, ELISA Development, ELISA Development (Capture), In vivo assay, Immunoassay Development

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 6708
View all IL-6 Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human IL-6

Specificity

Detects human and primate IL-6 in ELISAs and Western blots. In Western blots, this antibody does not cross-react with recombinant mouse (rm) IL‑6, rhOSM, rhLIF, rhIL‑11, rhgp130, or rhCNTF.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Endotoxin Level

<0.10 EU per 1 µg of the antibody by the LAL method.

Scientific Data Images for Human/Primate IL‑6 Antibody

Detection of Recombinant Human IL-6 antibody by Western Blot.

Detection of Recombinant Human IL‑6 by Western Blot.

Western blot shows 25 ng of Recombinant Human IL-6 (Catalog # 206-IL), Recombinant Mouse IL-6 (Catalog # 406-ML) and Recombinant Rat IL-6 (Catalog # 506-RL). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human/ Primate IL-6 Monoclonal Antibody (Catalog # MAB206) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IL-6 at approximately 18 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.
IL-6 antibody in Human Skin by Immunohistochemistry (IHC-Fr).

IL‑6 in Human Skin.

IL-6 was detected in immersion fixed frozen sections of hyperplastic human skin using Mouse Anti-Human/Primate IL-6 Monoclonal Antibody (Catalog # MAB206) at 8 µg/mL overnight at 4 °C. Tissue was stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent IHC Staining of Frozen Tissue Sections.
Cell Proliferation Induced by IL‑6 and Neutralization by Human IL‑6 Antibody.

Cell Proliferation Induced by IL‑6 and Neutralization by Human IL‑6 Antibody.

Recombinant Human IL-6 (Catalog # 206-IL) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL-6 (2.5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Primate IL-6 Monoclonal Antibody (Catalog # MAB206). The ND50 is typically 8.00 - 80.0 ng/mL.
Detection of Human IL-6 by Immunohistochemistry

Detection of Human IL-6 by Immunohistochemistry

The role of IL‐6 signaling in the upregulation of PD‐L1 and downregulation of NKG2D ligands in CRPC cells. (A) PD‐L1 level in C4‐2siIL‐6/sc and CWRsiIL‐6/sc cell lines (left panel, mRNA level; right panel, protein level). (B) PD‐L1 IHC staining of tumor tissues. Error bars and significance values were obtained by counting positively stained cells in one randomly chosen phase of slides of three different stains. Magnification, 20× (inlet, 100×). (C) Blocking of IL‐6 Ab by neutralizing Ab of IL‐6 and the effect on PD‐L1 level in C4‐2sc and CWRsc cells. Cells were treated with either IL‐6 Ab or control IgG, total RNA extracted, cDNA converted, and the expression of PD‐L1 was compared in qPCR analyses. (D) PD‐L1 level in parental C4‐2 and CWR22Rv1 cells upon the addition of rhIL‐6. Parental cells (C4‐2P and CWR22Rv1P) were treated with rhIL‐6 (20 ng·mL−1) and PD‐L1 mRNA level was analyzed. (E) IHC staining of CRPC patient tumor samples. Two sets of adjacent tumor tissues (both samples, CRPC stage, Gleason score 8, patient age 70, Ningbo hospital in China) were stained with IL‐6 and PD‐L1. Arrows indicate the area showing positive staining of two molecules. (F) NKG2D ligand levels in IL‐6‐expressing cells and in IL‐6‐knockdown cells. Levels of five NKG2D ligands in C4‐2siIL‐6/sc and CWRsiIL‐6/sc cells were analyzed in qPCR analyses. (G) NKG2D ligand levels in parental C4‐2 and CWR22Rv1 cells upon the addition of rhIL‐6. Parental cells (C4‐2P and CWR22Rv1P) were treated with rhIL‐6 (20 ng·mL−1) and the NKG2D ligand levels (mRNA) were analyzed. (H) Flow cytometric analyses of NKG2D and PD‐1 on NK cells. Left two panels, primary NK cells were stained with PE‐NKG2D or APC‐PD‐1 and positive staining was analyzed. Right two panels, flow cytometric analyses of PD‐1 on NK cells, after coculture with tumor cells (6 h of incubation). Primary NK cells were added into tumor cells (1 : 1 ratio, tumor cells/NK cells) and collected after 6 h of incubation. PD‐1 levels in the collected NK cells were analyzed in flow cytometric analysis (using APC‐PD‐1 Ab). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28865178), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human IL-6 by Western Blot

Detection of Human IL-6 by Western Blot

Autocrine IL-6 activates STAT3 signalling in lung cancer cell-induced epidural ADSCs. a Epidural ADSCs were pre-treated with CM from lung cancer cells for 48 h, and pSTAT3 and STAT3 expression levels were detected by western blotting. Epidural ADSCs cultured in untreated medium served as a control. b The effects of lung cancer cell CM on epidural ADSC proliferation were evaluated using the CCK-8 assay. Epidural ADSCs were treated with CM from one of four lung cancer cell lines, and the optical density of both groups at 450 nm was analysed. Data from three separate experiments are shown. c Western blot analysis of pSTAT3 and STAT3 in epidural ADSCs treated with either 10 ng/mL recombinant IL-6, 10 ng/mL recombinant IL-11 or 50 ng/mL recombinant LIF in the presence or absence of either neutralizing antibodies or isotype controls. Loading control, actin. d Western blot analysis of pSTAT3 and alpha -SMA expression in epidural ADSCs treated with lung cancer cell CM in the presence or absence of neutralizing antibodies against IL-6, IL-11 or LIF. Loading control, actin. *P < 0.05; **P < 0.01; ***P < 0.001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31196220), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human IL-6 by Western Blot

Detection of Human IL-6 by Western Blot

Autocrine IL-6 activates STAT3 signalling in lung cancer cell-induced epidural ADSCs. a Epidural ADSCs were pre-treated with CM from lung cancer cells for 48 h, and pSTAT3 and STAT3 expression levels were detected by western blotting. Epidural ADSCs cultured in untreated medium served as a control. b The effects of lung cancer cell CM on epidural ADSC proliferation were evaluated using the CCK-8 assay. Epidural ADSCs were treated with CM from one of four lung cancer cell lines, and the optical density of both groups at 450 nm was analysed. Data from three separate experiments are shown. c Western blot analysis of pSTAT3 and STAT3 in epidural ADSCs treated with either 10 ng/mL recombinant IL-6, 10 ng/mL recombinant IL-11 or 50 ng/mL recombinant LIF in the presence or absence of either neutralizing antibodies or isotype controls. Loading control, actin. d Western blot analysis of pSTAT3 and alpha -SMA expression in epidural ADSCs treated with lung cancer cell CM in the presence or absence of neutralizing antibodies against IL-6, IL-11 or LIF. Loading control, actin. *P < 0.05; **P < 0.01; ***P < 0.001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31196220), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human IL-6 by Western Blot

Detection of Human IL-6 by Western Blot

Activated ADSCs trigger the proliferation and invasion of lung cancer cells by regulating MMP2/9 expression and EMT. a The effects of activated ADSCs on lung cancer cell proliferation were evaluated using the CCK-8 assay. Four lung cancer cell lines were cultured in the presence of ADSC-CM or aADSC-CM, and the optical density at 450 nm was analysed. The cancer cells cultured alone in normal growth medium were used as negative controls. Data from three separate experiments are shown. b The number of lung cancer cells that migrated through 8-μm Transwell membrane pores was counted to determine the changes in the invasive capabilities in response to CM from epidural ADSCs or aADSCs. c MMP2/9, E-cadherin and vimentin expression levels in four lung cancer cell lines treated with ADSC-CM or aADSC-CM were examined by western blotting. Lung cancer cells cultured in an untreated medium served as controls. d Lung cancer cells were treated with neutralizing antibodies against IL-6, isotype controls and aADSC-CM. Lung cancer cell invasion was analysed using a Transwell assay. Lung cancer cells cultured with untreated medium served as negative controls. e Lung cancer cells were treated with neutralizing antibodies against IL-6, isotype controls and aADSC-CM. MMP2/9, E-cadherin and vimentin expression levels in four lung cancer cell lines were analysed using western blotting. Lung cancer cells cultured with untreated medium served as negative controls. ***P < 0.001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31196220), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human Human/Primate IL-6 Antibody by Western Blot

Detection of Human Human/Primate IL-6 Antibody by Western Blot

Musashi-1 mitigated DDP-induced apoptosis via the IL-6/AKT regulatory loopA. Cells were pretreated with 50 μM of LY294002 or vehicle for 3 hours, followed by 50 μM DDP treatment for 24 hours. The culture media were collected and the concentrations of IL-6 was determined by ELISA. B. 05MG-FlagMSI1 cells were treated with/without 50 μM DDP for 24 hours in the absence or presence of recombinant IL-6 (10 ng/ml) or anti-IL-6 neutralizing antibody (0.1 μg/ml). The cell lysates were analyzed by Western blot. C-D. The bar diagrams represent the quantified ratio of p-AKT-308/AKT and p-AKT-473/AKT obtained by the Western blot in B. E. 05MG cells were treated with control (serum free medium, S.F.) or condition media from 05MG-FlagMSI1 cells (C.M.) in the presence or absence of 50 μM DDP, IL-6 (10 ng/ml), and anti-IL-6 antibody (0.1 μg/ml) for 24 hours. The cell lysates were analyzed by Western blot to assess the levels of p-AKT-308, p-AKT-473, and total AKT. F-G. The bar diagrams represent the quantified ratio of p-AKT-308/AKT and p-AKT-473/AKT obtained in E. H. 05MG cells were treated as described in E and analyzed by Western blot. I-J. The bar diagrams represent the quantified ratio of cleavage-caspase-3/actin and cleaved-PARP/actin obtained in H. Data represent the mean ± S.D. of two independent experiments performed in triplicate. * P<0.05 vs AKT or Actin. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/27285760), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of IL-6 by Immunohistochemistry

Detection of IL-6 by Immunohistochemistry

circCUL2 regulates the phenotypic plasticity of CAFs and promote PDAC progression by IL6. A Gene Set Enrichment Analysis (GSEA) of affected signatures in fibroblasts (circCUL2 vs. control). B GSEA plots for inflammatory CAF (iCAF) signatures in circCUL2 overexpression NFs from control. C-D qRT–PCR analysis of iCAF markers (IL6, TNF-alpha and IL1 alpha ) and myCAF marker (Acta2 and Axin2) expression in circCUL2 overexpression NFs. E Flow cytometric analysis of PDGFR alpha and alpha -SMA expression in circCUL2 overexpression NFs. F-H. Representative cytokine arrays for circCUL2-overexpression NFs and control (n = 3). arrows indicate the cytokines with significant changes, which were further confirmed by qRT–PCR and ELISA. I-L EdU assay (I), colony formation (J), Scratch wound healing assays (K) and transwell assays (L) of PANC-1 cells treated with conditioned medium circCUL2-overexpression NFs or anti-IL6. Scale bar, 100 μm. M western blot analysis of STAT3 and p-STAT3 in PANC-1 cells. Data are expressed as the mean ± SD of three independent experiments. **p < 0.01 and ***p < 0.001 (two-tailed Student t-tests) Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35189958), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of IL-6 by Western Blot

Detection of IL-6 by Western Blot

circCUL2 regulates the phenotypic plasticity of CAFs and promote PDAC progression by IL6. A Gene Set Enrichment Analysis (GSEA) of affected signatures in fibroblasts (circCUL2 vs. control). B GSEA plots for inflammatory CAF (iCAF) signatures in circCUL2 overexpression NFs from control. C-D qRT–PCR analysis of iCAF markers (IL6, TNF-alpha and IL1 alpha ) and myCAF marker (Acta2 and Axin2) expression in circCUL2 overexpression NFs. E Flow cytometric analysis of PDGFR alpha and alpha -SMA expression in circCUL2 overexpression NFs. F-H. Representative cytokine arrays for circCUL2-overexpression NFs and control (n = 3). arrows indicate the cytokines with significant changes, which were further confirmed by qRT–PCR and ELISA. I-L EdU assay (I), colony formation (J), Scratch wound healing assays (K) and transwell assays (L) of PANC-1 cells treated with conditioned medium circCUL2-overexpression NFs or anti-IL6. Scale bar, 100 μm. M western blot analysis of STAT3 and p-STAT3 in PANC-1 cells. Data are expressed as the mean ± SD of three independent experiments. **p < 0.01 and ***p < 0.001 (two-tailed Student t-tests) Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35189958), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of IL-6 by Immunohistochemistry

Detection of IL-6 by Immunohistochemistry

circCUL2-overexpression NFs promote PDAC progression in vivo. A Representative Bioluminescence images, lung and HE staining of lung tissue of mice 4 weeks after tail vein injection of luc-PANC-1 cell treated with conditioned medium as indicated (n = 8 per group). Scale bar, 100 μm. B Relative luminescence intensity in each group. C Histogram analysis of the metastatic nodules number in per lung. D lung metastasis rate of each group (Chi-square test). E-F Representative bioluminescence images and histogram analysis of luminescence intensity in each at day 30 are shown (n = 6). G Abdominal metastasis rate was calculated for indicated group (Chi-square test). H Representative images of orthotopic model in each group on which autopsy was performed. Red arrow indicated primary tumor; S, spleen; T, primary tumor; M, metastasis. I Images of PDX from 2 patients in 5 mice. (J) Tumor growth curves of indicated group (n = 5). K qRT–PCR analysis of circCUL2 levels in PDX of mice before and after treatment. L Representative images of IHC for PDGFR alpha and IL6. Scale bar, 100 μm. Data are expressed as the mean ± SD. **p < 0.01 and ***p < 0.001 (two-tailed Student t-tests) Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35189958), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human/Primate IL‑6 Antibody

Application
Recommended Usage

Immunohistochemistry

8-25 µg/mL
Sample: Immersion fixed frozen sections of hyperplastic human skin

Western Blot

1 µg/mL
Sample: Recombinant Human IL‑6 (Catalog # 206-IL)

Neutralization

Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R.P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND50) is typically 8.00 - 80.0 ng/mL in the presence of 2.5 ng/mL Recombinant Human IL‑6.

Human/Primate IL-6 Sandwich Immunoassay

ELISA Capture (Matched Antibody Pair)
Recommended Concentration: 2-8 µg/mL
Use in combination with these reagents:
  • Detection Reagent: Human/Primate IL‑6 Biotinylated Antibody (Catalog # BAF206)
  • Standard: Recombinant Human IL-6 Protein (Catalog # 206-IL)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 16 reviews rated 4.5 using MAB206 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-6

Interleukin-6 (IL-6) is a pleiotropic, alpha -helical, phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. Mature human IL-6 is 183 amino acids (aa) in length expressed as a 22-28 kDA molecular weight protein. IL-6 shares 39% aa sequence identity with mouse and rat IL-6. Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties. IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization. gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor. IL-6, along with TNF-alpha and IL-1, function to drive the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis. IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise. In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells.

Long Name

Interleukin 6

Alternate Names

BSF-2, BSF2, IFNB2, IL6, MGI-2A

Entrez Gene IDs

3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 102138971 (Cynomolgus Monkey); 100034196 (Equine); 493687 (Feline); 463288 (Primate); 100008733 (Rabbit)

Gene Symbol

IL6

Additional IL-6 Products

Product Documents for Human/Primate IL‑6 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human/Primate IL‑6 Antibody

For research use only

Citations for Human/Primate IL‑6 Antibody

Customer Reviews for Human/Primate IL‑6 Antibody (16)

4.5 out of 5
16 Customer Ratings
5 Stars
50%
4 Stars
50%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Human/Primate IL‑6 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 5 of 16 reviews Showing All
Filter By:
Clear Filters X
  • Human/Primate IL-6 Antibody
    Name: Anonymous
    Application: Immunohistochemistry
    Sample Tested: Colon tissue
    Species: Human
    Verified Customer | Posted 03/17/2022
    Human/Primate IL‑6 Antibody MAB206
  • Human/Primate IL-6 Antibody
    Name: Anonymous
    Application: Immunohistochemistry-Frozen
    Sample Tested: Skin tissue
    Species: Human
    Verified Customer | Posted 01/21/2022
    IL-6 in human skin
    IL‑6 was detected in immersion fixed frozen sections at 8 ug/ml overnight at 4C.
    Human/Primate IL‑6 Antibody MAB206
  • Human/Primate IL-6 Antibody
    Name: Anonymous
    Application: Immunofluorescence
    Sample Tested: Brain (dorsal root ganglia)
    Species: Human
    Verified Customer | Posted 08/02/2021
    Human/Primate IL‑6 Antibody MAB206
  • Human/Primate IL-6 Antibody
    Name: Anonymous
    Application: Microarrays
    Sample Tested: EDTA Plasma
    Species: Human
    Verified Customer | Posted 06/10/2020
    Human/Primate IL‑6 Antibody MAB206
  • Human/Primate IL-6 MAb (Clone 6708)
    Name: Anonymous
    Application: Block/Neutralize
    Sample Tested: Serum-free Cell Culture Media and Breast cancer cells
    Species: Human
    Verified Customer | Posted 05/27/2019
  • Human/Primate IL-6 Antibody
    Name: Balaji Mahender
    Application: ELISA
    Sample Tested: EDTA Plasma
    Species: Human
    Verified Customer | Posted 12/19/2018
  • Human/Primate IL-6 Antibody
    Name: Anonymous
    Application: Microarray
    Sample Tested: EDTA Plasma
    Species: Human
    Verified Customer | Posted 11/20/2018
  • Human/Primate IL-6 Antibody
    Name: Anonymous
    Application: Microarrays
    Sample Tested: EDTA Plasma
    Species: Human
    Verified Customer | Posted 11/07/2018
  • Human/Primate IL-6 Antibody
    Name: Zoia Levashova
    Application: MSD assay
    Sample Tested: Vitreous humor
    Species: Cynomolgus Monkey
    Verified Customer | Posted 11/01/2018
    After biotinylation, used as a capture reagent according to the manufacturer’s protocol (Meso Scale Diagnostics LLC). Paired with goat PC IL-6 antibody (AF-206-NA) as a detection antibody. A standard curve with recombinant human IL-6 (Cat# 206-IL/CF) is shown (1.6-25,000 pg/ml).
    Human/Primate IL‑6 Antibody MAB206
  • Human/Primate IL-6 Antibody
    Name: Danlee Enzler
    Application: Immunohistochemistry
    Sample Tested: Spleen tissue
    Species: Human
    Verified Customer | Posted 04/24/2018
  • Human/Primate IL-6 Antibody
    Name: Leslie Priddy
    Application: Western Blot
    Sample Tested: Tumor cell lyastes
    Species: Human
    Verified Customer | Posted 04/13/2018
  • Human/Primate IL-6 Antibody
    Name: Anonymous
    Application: Immunocytochemistry/Immunofluorescence
    Sample Tested: Human affected ileum tissue from Crohn's patients
    Species: Human ileum tissue and Human normal resection margin tissue from Crohn's patients
    Verified Customer | Posted 03/30/2018
    Li C, Iness A, Yoon J, Grider JR, Murthy KS, Kellum JM, Kuemmerle JF. Increased autocrine IL-6 and STAT3 (Ser727) phosphorylation is profibrotic regulating TGF-beta 1 and Collagen I in muscle of stricturing Crohn's disease. J Immunol. 194(7):3422-31; 2015
    Human/Primate IL‑6 Antibody MAB206
  • Name: Anonymous
    Application: Western Blot
    Sample Tested: Human recombinant test antibody
    Species: Human
    Verified Customer | Posted 03/23/2018
  • Human/Primate IL-6 Antibody
    Name: Qing Zhang
    Application: Functional Assay
    Sample Tested: Kidney cancer cells
    Species: Human
    Verified Customer | Posted 05/16/2017
  • Human/Primate IL-6 Antibody
    Name: Michelle Chen
    Application: Block/Neutralize
    Sample Tested: Neutrophils
    Species: Human
    Verified Customer | Posted 04/26/2017
    IL-6 secretion was neutralized in neutrophils and its effect on tumor cell extravasation was assessed.
    Human/Primate IL‑6 Antibody MAB206
  • Human/Primate IL-6 Antibody
    Name: Ruhul Choudhury
    Application: Immunohistochemistry-Paraffin
    Sample Tested: First trimester human decidua
    Species: Human
    Verified Customer | Posted 03/16/2017
    20X magnification. IL-6 expressed in decidual stromal cells, although absent in smooth muscle cells of Spiral artery.
    Sodium Citrate antigen retrieval
    Human/Primate IL‑6 Antibody MAB206

There are no reviews that match your criteria.

Showing  1 - 5 of 16 reviews Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for Human/Primate IL‑6 Antibody

Showing  1 - 2 of 2 FAQs Showing All

  • Q: What is the light chain of Human/Primate IL-6 Antibody, Catalog # MAB206, Clone # 6708?

    A: Catalog # MAB206 has a kappa light chain.

  • Q: Which R&D Systems antibody product could be used as an isotype control for catalog # MAB206?

    A: Catalog # MAB002 or MAB002R (Mouse IgG1 isotype control) could be used as a control for catalog # MAB206.

  • Q: What is the light chain of Human/Primate IL-6 Antibody, Catalog # MAB206, Clone # 6708?

    A: Catalog # MAB206 has a kappa light chain.

  • Q: Which R&D Systems antibody product could be used as an isotype control for catalog # MAB206?

    A: Catalog # MAB002 or MAB002R (Mouse IgG1 isotype control) could be used as a control for catalog # MAB206.

Showing  1 - 2 of 2 FAQs Showing All
View all FAQs for Antibodies